Chemomab Therapeutics (CMMB) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Chemomab Therapeutics (CMMB) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 53.0% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMMB | RADX |
|---|---|---|
| Share price | $1.19 | $0.6304 |
| Market cap | $9.58M | $9.90M |
| 1-day change | +4.39% | -9.71% |
| YTD return | -27.88% | -87.92% |
| 1-year return | -52.96% | -86.15% |
| 5-year return | -96.65% | — |
| EPS (TTM) | $-1.04 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.63M |
| Revenue growth (YoY) | — | +1114.27% |
| Net income (latest FY) | $-8.99M | $-38.34M |
| Gross margin | — | 1.08% |
| Operating margin | — | -1050.63% |
| Net margin | — | -1055.27% |
| 52-week high | $2.99 | $16.25 |
| 52-week low | $0.92 | $0.63 |
| Distance from 52-week high | -60.20% | -96.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +320.17% | +2595.11% |
| Average volume | 102.39K | 55.23K |
| Shares outstanding | 8.05M | 15.70M |
| Employees | — | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMMB has outperformed RADX by 33.2 percentage points over the past year.
About Chemomab Therapeutics
CMMB stock →Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
CMMB vs RADX FAQ
Which is bigger, Chemomab Therapeutics or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.58M for Chemomab Therapeutics (CMMB).
Which stock has performed better over the past year, CMMB or RADX?
CMMB returned -52.96% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Chemomab Therapeutics and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.